Contact this trialFirst, we need to learn more about you.
Interleukin-6 (IL-6) Receptor Antagonist
Upadacitinib + Tocilizumab for Juvenile Idiopathic Arthritis
Recruiting2 awardsPhase 3
Valhalla, New York
This trial is evaluating a potential new treatment for juvenile idiopathic arthritis, a chronic disease that affects children and can continue into adulthood. Participants will receive either upadacitinib or tocilizumab and be assessed for adverse events and disease activity.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service